Corporate & Investor Presentation slide image

Corporate & Investor Presentation

47 Big data analysis demonstrates CPAP treatment decreases mortality rates by 39% Objective: to investigate the effects of CPAP therapy use on all-cause mortality in patients with OSA . ALASKA study conducted using data from SNDS, one of the largest anonymized claims databases in the world representing over 99% of the French population - Included >176,000 people in France ― New CPAP users aged 18+, initiated treatment Jan'15-Dec' 16 . OSA patients who continued CPAP therapy over the 3-year study period were 39% more likely to survive than those who discontinued CPAP therapy 1. Pepin JL et al. Chest 2022 Survival probability 1.00 0.98 0.96 0.94 CPAP therapy termination CPAP therapy continuation HR 0.61, 95% confidence interval [CI] 0.57-0.65; Log-rank p<0.01 0 0 1 2 3 Time [years] CPAP treatment is a case of life or death © 2022 ResMed | Corporate & Investor Presentation - updated 28APR22 ResMed
View entire presentation